CARSGEN-B (02171) announces its interim results with a net loss of 75.48 million yuan, a year-on-year decrease of 78.53%.
Kozi Pharmaceutical-B (02171) announced its mid-term performance for 2025, with a profit of 50.961 million RMB, a year-on-year increase...
CARSGEN-B (02171) announced its mid-term performance for 2025, with a profit of 50.961 million yuan, an increase of 703.8% year-on-year; a gross profit of 29.369 million yuan, an increase of approximately 17.16 times year-on-year; a net loss of 75.483 million yuan, which narrowed by 78.53% year-on-year; and a loss per share of 0.14 yuan.
The announcement stated that the decrease in losses was mainly due to a reduction in research and development expenses, a reduction in administrative expenses, an increase in net foreign exchange gains, and an increase in gross profit.
Related Articles

Software crashed together? Roblox (RBLX.US): It has an ecological closed-loop, Genie can't break.

Industrial: Hong Kong stock market sentiment index has reached the bottom area.

"The 'Chinese Choice' for Global SiC Core Customers: Why TIANYU SEMI (02658)?"
Software crashed together? Roblox (RBLX.US): It has an ecological closed-loop, Genie can't break.

Industrial: Hong Kong stock market sentiment index has reached the bottom area.

"The 'Chinese Choice' for Global SiC Core Customers: Why TIANYU SEMI (02658)?"

RECOMMEND

Nine Companies With Market Value Over RMB 100 Billion Awaiting, Hong Kong IPO Boom Continues Into 2026
07/02/2026

Hong Kong IPO Cornerstone Investments Surge: HKD 18.52 Billion In First Month, Up More Than 13 Times Year‑On‑Year
07/02/2026

Over 400 Companies Lined Up For Hong Kong IPOs; HKEX Says Market Can Absorb
07/02/2026


